Slide 1: Half Year Results Presentation
Atomo Diagnostics Limited Authorised by John Kelly, Managing Director 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia For personal use only Half Year Results Presentation 22 February 2022 ATOMO ATOMO DIAGNOSTICS DIAGNOSTICS LIMITED|| (ASX: LIMITED (ASX: AT1) AT1)
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on communications transmitted or otherwise made available to the recipient in information available as at the date of this presentation. The information in this connection with the oppor
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is an innovative medical For personal use only device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to the global market Headquartered in Australia with international opera
Slide 4: H1 FY22 – Profit and Loss
H1 FY22 – PROFIT AND LOSS For personal use only • Overall gross revenue from customers increased by 53% to $7.0m (vs PCP H1 FY21), driven by: • Total sales from ordinary operating activities was $5.34m during the period. In • strong demand for COVID-19 point of care tests addition, revenue of $1.65m
Slide 5: H1 FY22 – Balance Sheet
H1 FY22 – BALANCE SHEET For personal use only • Trade receivables were lower at 31 December 2021, as the proportion of sales related to COVID-19 rapid antigen testing in Australia increased, where customers are on shorter payment terms when compared with OEM and HIV customers • Total R&D spend for H
Slide 6: H1 FY22 – Cashflow Activities
H1 FY22 – CASHFLOW ACTIVITIES For personal use only • Cash receipts of $7.73m for the half, underpinned by demand for COVID-19 rapid antigen test sales and growth in HIV sales • R&D Tax rebate of $1.8m received • Cash outflows predominantly consisting of: • payments for stock to meet demand from cus
Slide 7: A Permanently Changed Diagnostic Market
A PERMANENTLY CHANGED DIAGNOSTIC MARKET Tailwinds and headwinds HIV For personal use only Near Term • Immediate revenue growth opportunities in COVID rapid testing resulting from an unprecedented global pandemic • A contraction of IVD industry new product Medium Term commercialisation pipelines and
Slide 8: Atomo's Core Capabilities
ATOMO’S CORE CAPABILITIES The intersection between Medical Devices & Diagnostics For personal use only Less IP Intensive IP Intensive More sales focused Atomo DNA Core Functionality Devices Finished Products Customer Delivery Point-of-Care Self Testing • Blood collection • Galileo • HIV • Atomo Dire
Slide 9: Atomo's Operational Footprint
ATOMO’S OPERATIONAL FOOTPRINT For personal use only Europe Asia North America • HIV ST, Blood based • Cassette moulding and assembly pregnancy and FebriDx all (Current Annual Manufacturing • Biggest partnership CE Marked Capacity: ~20M) opportunities • OEM partners: NG Biotech • Seeking China market
Slide 10: Atomo's Strategic Focus
ATOMO’S STRATEGIC FOCUS HIV For personal use only Core Capabilities Innovation, Co-development & Commercialisation (device design, usability, manufacturability, IP, regulatory, co-commercialisation) Markets Infectious Rapid Test Consumer Health Diseases Testing Devices & Wellness (HIV, COVID, Others
Slide 11: A Growing Infectious Disease Business
Market A GROWING INFECTIOUS DISEASE BUSINESS HIV For personal use only HIV OTHER TESTS COVID-19 Antigen - Australia Atomo has an opportunity to continue to meet demand for COVID-19 testing in Australian and NZ markets OEM Devices for Respiratory applications Atomo’s swab device improves usability an
Slide 12: Rapid Testing in Australia
Market RAPID TESTING IN AUSTRALIA HIV For personal use only COVID-19 TESTING SUMMARY • Australia demonstrated significant demand for rapid COVID-19 tests in late 2021 after roll-out delays due to resistant public health policy • Atomo sold 420k rapid COVID tests during H1 FY22, with product sales in
Slide 13: OEM Market – Atomo Rapid Test Devices: Unique Solutions
OEM MARKET – ATOMO RAPID TEST DEVICES: UNIQUE SOLUTIONS For personal use only Accelerate roll-out of current solutions with existing Leverage existing approvals, with potential for partners to upgrade existing blood platforms products to an Atomo cassette or commercialise their new tests using Atomo
Slide 14: Clinic at Home – The Next Healthcare Frontier
CLINIC AT HOME – THE NEXT HEALTHCARE FRONTIER two thirds of all clinical decisions are For personal use only based on a diagnostic test Strategic Opportunity / home testing market: Rapidly emerging new market for eHealth enabled healthcare in the home, cannibalising lab/clinic-based models as well a